X4 Pharmaceuticals Report Positive Results from Clinical Trial Treating Advanced Clear Cell Renal Cell Carcinoma Patients

X4 Pharmaceuticals Report Positive Results from Clinical Trial Treating Advanced Clear Cell Renal Cell Carcinoma Patients

Subgroup exceeds target of 50% improvement in median progression-free survival, and 12% of patients remain on combination treatment with durations of 17 months or longer in X4 Pharmaceuticals’ Phase 2a portion of its open-label Phase 1/2 clinical trial of mavorixafor...
Merger Between American Cryostem Corporation And Biosolutions Clinical Research Center, LLC: What This Means For Military Personnel and Athletes

Merger Between American Cryostem Corporation And Biosolutions Clinical Research Center, LLC: What This Means For Military Personnel and Athletes

Cryostem and Biosolutions are conducting a first-of-its-kind cellular therapy clinical study as part of the protocol entitled: ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion...

Pin It on Pinterest